We are live on ! Find out more
AMPH icon

Amphastar Pharmaceuticals

95 hedge funds and large institutions have $213M invested in Amphastar Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 47 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,825% more call options, than puts

Call options by funds: $197K | Put options by funds: $4K

81% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 26

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

33% more capital invested

Capital invested by funds: $160M → $213M (+$52.3M)

3% more funds holding

Funds holding: 9295 (+3)

Holders
95
Holders Change
+3
Holders Change %
+3.26%
% of All Funds
2.49%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
47
Reduced
26
Closed
8
Calls
$197K
Puts
$4K
Net Calls
+$193K
Net Calls Change
+$202K
Name Holding Trade Value Shares
Change
Change in
Stake
RhumbLine Advisers
51
RhumbLine Advisers
Massachusetts
$495K +$31.5K +2,385 +7%
New York State Common Retirement Fund
52
New York State Common Retirement Fund
New York
$464K
TI
53
Trexquant Investment
Connecticut
$460K +$427K +32,300 New
EIM
54
Essex Investment Management
Massachusetts
$446K -$102K -7,700 -20%
AllianceBernstein
55
AllianceBernstein
Tennessee
$413K +$4.23K +320 +1%
CS
56
Credit Suisse
Switzerland
$391K -$289K -21,880 -44%
AQR Capital Management
57
AQR Capital Management
Connecticut
$388K +$40.7K +3,080 +13%
PCM
58
Prelude Capital Management
New York
$377K +$71.3K +5,400 +26%
BGIM
59
Brandywine Global Investment Management
Pennsylvania
$345K +$216K +16,345 +207%
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
$337K +$15.7K +1,191 +5%
DekaBank Deutsche Girozentrale
61
DekaBank Deutsche Girozentrale
Germany
$331K +$7.92K +600 +3%
ACI
62
AMP Capital Investors
Australia
$312K +$48.5K +3,672 +20%
ARTA
63
A.R.T. Advisors
New York
$306K +$23.8K +1,800 +9%
UBS Group
64
UBS Group
Switzerland
$292K +$243K +18,429 +859%
Capital Fund Management (CFM)
65
Capital Fund Management (CFM)
France
$270K +$251K +18,974 New
AIG
66
American International Group
New York
$265K -$436 -33 -0.2%
Citigroup
67
Citigroup
New York
$257K +$184K +13,935 +336%
FCE
68
Fiera Capital (Europe)
Cayman Islands
$210K +$82.2K +6,220 +74%
VOYA Investment Management
69
VOYA Investment Management
Georgia
$205K
Wells Fargo
70
Wells Fargo
California
$181K +$68.7K +5,202 +69%
GC
71
Globeflex Capital
California
$172K +$160K +12,086 New
BA
72
BlackRock Advisors
Delaware
$171K -$40.8K -3,088 -20%
GCP
73
GSA Capital Partners
United Kingdom
$164K -$13K -986 -8%
DTL
74
Dynamic Technology Lab
Singapore
$156K +$145K +10,995 New
Citadel Advisors
75
Citadel Advisors
Florida
$147K +$137K +10,336 New

AMPH Hedge Fund Activity: Q4 2015 in Review

95 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2015, worth a combined $213M — up 33% from $160M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AMPH positions and 8 closed out — a net gain of 3 holders — while 47 added to existing stakes and 26 trimmed.

The largest buyer was Teachers Advisors, adding an estimated $4.17M. The largest seller was UBS AM, cutting an estimated $3.57M.

  • 95 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2015, up from 92 in Q3 2015.
  • Funds reported $213M of Amphastar Pharmaceuticals stock for Q4 2015, up 33% quarter-over-quarter.
  • 11 funds opened new Amphastar Pharmaceuticals positions in Q4 2015 and 8 closed out, a net change of +3 holders.
  • The largest Amphastar Pharmaceuticals buyer in Q4 2015 was Teachers Advisors, an estimated $4.17M added.
  • The largest Amphastar Pharmaceuticals seller in Q4 2015 was UBS AM, an estimated $3.57M sold.

Based on aggregated 13F filings for Q4 2015.